Abstract
PolyomavirusBK(BKPyV) infects most people subclinically during childhood and establishes a lifelong infection in the renourinary tract. In most immunocompetent individuals, the infection is completely asymptomatic, despite frequent episodes of viral reactivation with shedding into the urine. In immunocompromised patients, reactivation followed by high‐level viral replication can lead to severe disease: 1–10% of kidney transplant patients develop polyomavirus‐associated nephropathy (PyVAN) and 5–15% of allogenic hematopoietic stem cell transplant patients develop polyomavirus‐associated haemorrhagic cystitis (PyVHC). Other conditions such as ureteric stenosis, encephalitis, meningoencephalitis, pneumonia and vasculopathy have also been associated withBKPyVinfection in immunocompromised individuals. AlthoughBKPyVhas been associated with cancer development, especially in the bladder, definitive evidence of a role in human malignancy is lacking. Diagnosis ofPyVANandPyVHCis mainly achieved by quantitativePCRof urine and plasma, but also by cytology, immunohistology and electron microscopy. Despite more than 40 years of research onBKPyV, there is still no effective antiviral therapy. The current treatment strategy forPyVANis to allow reconstitution of immune function by reducing or changing the immunosuppressive medication. ForPyVHC, treatment is purely supportive. Here, we present a summary of the accrued knowledge regardingBKPyV.

This publication has 172 references indexed in Scilit: